ClinicalTrials.gg
TerminatedNCT03690739Updated Feb 24, 2022

Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

A Phase 3 interventional study of Carboplatin and Gemcitabine in Recurrent Ovarian Carcinoma, sponsored by AGO Research GmbH. Terminated at 29 sites in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-24.

Sponsored by AGO Research GmbH · Phase 3, Interventional, and Prevention

Why this study was terminated
Insufficient Recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 166 studies testing carboplatin in Ovarian Neoplasms — 14 open to participants now, 21 under way, 6 of them phase 3. Carboplatin · Ovarian Neoplasms.

Enrollment
135th of 150
9 · median 48
Started
2019
with 4 others
Phase 3
25 of 166
4 open now
Registered
141st of 166
by date

Among the 166 studies testing carboplatin in Ovarian Neoplasms, this one is the 135th largest by enrollment of the 150 interventional ones that give a count, is one of 5 that started in 2019, is one of 25 in phase 3, and was the 141st registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

14 of the 166 studies testing carboplatin in Ovarian Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carboplatin

Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 166 studies testing carboplatin in Ovarian Neoplasms, or all of them as a file.
02

Study summary

This is an open-label, prospective, randomized, controlled, parallel group, multi-center phase III trial to evaluate the Symptom Benefit Rate of trabectedin/PLD in patients with recurrent ovarian cancer who achieve a stabilization of disease after 3 cycles of platinum-based reinduction therapy and with no clinical benefit.

Read the detailed description

Approximately 330 patients will be randomized in a 1:1 ration to the treatments specified below:

Arm A - Platinum-based chemotherapy according to investigator's discretion Arm B - Pegylated liposomal doxorubicin 30 mg/m² + Trabectedin 1.1 mg/m² (q3w)

03

Conditions studied

  • Recurrent Ovarian Carcinoma

Browse trials for

Keywords

  • Symptom Benefit
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Females aged ≥ 18 years at time of signing form.
  2. proven diagnosis of cancer of the ovary, the fallopian tube or primary peritoneal cancer.
  3. Measurable or non- (according v1.1) or CA-125 assessable disease (according GCIG criteria) or histologically proven diagnosis of relapse.
  4. Platinum-treatment free interval (TFIp) > 6 months prior to cycle 1 day 1 of reinduction therapy.
  5. Disease stabilization without remission or progression ac-cording to RECIST or GCIG criteria after three cycles of platinum-based chemotherapy for recurrent disease.
  6. Symptomatic disease at time of baseline abdominal/GI symptom scale score >15 (EORTC QLQ-OV28)
  7. Completion of EORTC QLQ-OV28 at Baseline within 7 days prior to treatment start.
  8. Patients should have received previously a taxane derivative.
  9. performance status ≤ 2.
  10. of at least 12 weeks.
  11. Adequate bone marrow, renal and hepatic function defined as:

    • (ANC) ≥ 1.5 x 10\^9/L
    • count ≥ 100 x 10\^9/L
    • ≥ 9.0 g/dL
    • Serum creatinine ≤1.5 mg/dL (≤ 132.6 µmol/L) or ≥ 60 mL/min
    • Creatine phosphokinase (CPK) ≤ 2.5 x
    • Serum (AST, SGOT) or alanine aminotransferase (ALT, SGPT) ≤ 2.5 x ULN (≤ 5 x ULN in the presence of liver )
    • Alkaline phosphatase (ALP) ≤ 2.5 ULN
    • Serum ≤ ULN
    • Albumin ≥ 25 g/l
  12. Participation in an informed consent discussion with the appropriate trial-related health care representative, full understanding of the implications and constraints of the protocol, and provision of written informed consent prior to the commencement of the trial-related procedures.
  13. Geographically accessibility for treatment and follow-up.
  14. For women of (WOCBP): agreement to remain abstinent (refrain from heterosexual inter-course) or use a method with a failure rate of \< 1 per-centage per year during the treatment period and for at least six months after administration of the last dose of chemo-therapy. A woman is considered to be of childbearing po-tential if she is postmenarcheal, has not reached a state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries, fal-lopian tubes, and/or uterus). Examples of contraceptive methods with a failure rate of \< 1 percentage per year in-clude but are not limited to bilateral tubal ligation and/or oc-clusion, male sterilization, and intrauterine devices, and nor-mal and low dose combined oral pill plus male condom or Cerazette (desogestrel) plus male condom. Cerazette is currently the only highly efficacious progesterone based pill. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation meth-ods) and withdrawal are not acceptable methods of contra-ception.

Exclusion criteria

Exclusion Criteria:

  1. Ovarian tumors of low malignant potential (e.g. borderline tumors).
  2. Non-epithelial ovarian or mixed epithelial/non epithelial tumors (e.g. mixed Müllerian tumors).
  3. Patients with an objective response in terms of a partial or complete remission or alternatively progressive disease ac-cording to or GCIG criteria after three cycles of platinum-based reinduction chemotherapy.
  4. Patients who have received previous radiotherapy for ovarian cancer.
  5. History of congestive heart failure ( classification > 2, even if medically con-trolled).
  6. History of myocardial infarction within the last six months (documented or by ).
  7. History of atrial or ventricular arrhythmias.
  8. Impaired liver function, hyperbilirubinemia, Serum creatinine >1.5 mg/dL or > 132.6 μmol/L or \< 60 mL/min, \< 45 %.
  9. Severe active or uncontrolled infection.
  10. Concurrent severe medical problems unrelated to , which would significantly limit full compliance with the trial or expose the patient to extreme risk or decreased .
  11. Patients with known to the active substance or their compounds related to trabectedin or PLD and patients with known hypersensitivity to one of active substances or one of their compounds used in platinum-based chemotherapy as described in the Summaries of Medicinal Products.
  12. Patients with potential risks according to , warnings or interactions of the used chemotherapeutic agents as stated in the SmPCs are not eligible for participation in this trial.
  13. Patients with contraindication regarding CT or MRI (only in case of contrast allergy) are excluded.
  14. Women of (WOCBP) not using highly effective methods.
  15. Pregnancy or breast-feeding.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Active comparator
    platinum-based chemotherapy

    According to the investigator's discretion

    Drug: Carboplatin · Drug: Gemcitabine · Drug: Bevacizumab · Drug: PLD · Drug: Paclitaxel · Drug: Cisplatin

  • Active comparator
    PLD + Trabectedin

    PLD 30 mg/m² + Trabectedin 1.1 mg/m² q21

    Drug: PLD · Drug: Trabectedin

Interventions

  • Administration according to investigator's discretion

  • Administration according to investigator's discretion

  • Administration according to investigator's discretion

  • DrugPLD

    Administration according to investigator's discretion

  • Administration according to investigator's discretion

  • DrugPLD

    Administration 30 mg/m² q21

  • Administration 1.1 mg/m² q21

  • Administration according to investigator's discretion

06

What researchers measure

Primary outcomes

  1. Symptom Benefit Rate

    Proportion of patients achieving a symptom benefit defined as an at least 10-point improvement according to EORTC QLQ-OV28; EORTC QLQ-OV28 is a questionnaire regarding Quality of Life specialized for Ovarian Cancer with points from 1 till 4 for each of the 28 questions (1=not at all, 2=a little, 3=quite a bit, 4=very much). Points will be summarized.

    Time frame: from Baseline to 8 or 9 weeks after randomization, assessed at each visit

Secondary outcomes

  1. Time until definitive deterioration (TUDD )

    TUDD is defined as time from baseline until the first decrease in EORTC QLQ-C30 score ≥ 10 points (or 20 points) as compared at baseline; EORTC QLQ-C30 is a questionnaire regarding Quality of Life specialized for Cancer with points for each of the 30 questions (1=not at all, 2=a little, 3=quite a bit, 4=very much). Points will be summarized.

    Time frame: from Baseline until 24 months after randomization, assessed up to 54 months at each visit

  2. Progression-free survival (PFS)

    Progressive disease is based on investigator assessment using RECIST v1.1

    Time frame: PFS is defined as time from randomization to disease progression according to RECIST v1.1, to death from any cause or to start of a new treatment (whichever occurs first), assessed up to 54 months

  3. Progression-free survival (PFS) rate at 6 months

    Progressive disease is based on investigator assessment using RECIST v1.1

    Time frame: PFS is defined as time from randomization to disease progression according to RECIST v1.1, to death from any cause or to start of a new treatment (whichever occurs first) after six months

  4. Response Rate (RR)

    RR is based on investigator assessment using RECIST v1.1

    Time frame: from randomization until patients achieving complete response (CR) or partial response (PR) as best overall response, assessed up to 54 months

  5. Global Health Status

    based on Quality of Life; EORTC QLQ-C30 and EORTC QLQ-OV 28 are questionnaires for Quality of Life with points for each of the 30 or 28 questions (1=not at all, 2=a little, 3=quite a bit, 4=very much). Points will be summarized.

    Time frame: from baseline to end of treatment, assessed up to 54 months at each visit

  6. Overall Survival (OS)

    regular patient contact during the trila regarding life status

    Time frame: OS is defined as the time from randomization to death from any cause, assessed up to 54 months

07

Study locations

29 sites
  • Klinikum Aschaffenburg-Alzenau
    Aschaffenburg, Bayern 63739, Germany
  • Hochtaunus-Kliniken
    Bad Homburg, Germany
  • Sozialstiftung Bamberg
    Bamberg, Germany
  • Evangelisches Krankenhaus Bergisch Gladbach
    Bergisch Gladbach, Germany
  • Charité - Universitätsmedizin Berlin
    Berlin, Germany
  • Universitätsfrauenklinik Bonn
    Bonn, Germany
  • Schwerpunktpraxis für Onkologie / Hämatologie
    Bottrop, Germany
  • Frauenärzte Casparistraße
    Braunschweig, Germany
  • Universitätsklinikum Carl Gustav Carus
    Dresden, Germany
  • Evang. Kliniken Essen-Mitte
    Essen, Germany
  • Agaplesion Markus Krankenhaus
    Frankfurt, Germany
  • Universitätsmedizin Greifswald
    Greifswald, Germany
  • Mammazentrum Hamburg am Krankenhaus Jerusalem
    Hamburg, Germany
  • Klinikum Itzehoe
    Itzehoe, Germany
  • ViDia Christliche Kliniken Karlsruhe
    Karlsruhe, Germany
  • Klinikum Ludwigsburg
    Ludwigsburg, Germany
  • Klinikum Magdeburg
    Magdeburg, Germany
  • Katholisches Klinikum Mainz
    Mainz, Germany
  • Universitätsfrauenklinik Mannheim
    Mannheim, Germany
  • Klinikum Memmingen
    Memmingen, Germany
  • Klinikum rechts der Isar
    München, Germany
  • Kliniken des Landkreises Neumarkt
    Neumarkt, Germany
  • Universitätsklinik für Innere Medizin, Onkologie und Hämatologie
    Oldenburg, Germany
  • Klinikum Ernst von Bergmann
    Potsdam, Germany
  • Agaplesion Diakonieklinikum Rotenburg
    Rotenburg, Germany
  • Thüringen Kliniken "Georgius Agricola"
    Saalfeld, Germany
  • g.Sund Gyn. Kompetenzzentrum
    Stralsund, Germany
  • Kreiskrankenhaus "Johann Kentmann"
    Torgau, Germany
  • Helios Dr. Horst Schmidt Kliniken
    Wiesbaden, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Mar 2021, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2018
First posted
Oct 1, 2018
StartActual
Aug 9, 2019
Primary completionActual
Mar 3, 2021
CompletionActual
Mar 3, 2021
Last update
Feb 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03690739
Lead sponsor
AGO Research GmbH
Responsible party
Sponsor
First posted
Oct 1, 2018
Start date
Aug 9, 2019
Primary completion
Mar 3, 2021
Completion
Mar 3, 2021
Last update
Feb 24, 2022

Study contacts

Felix Hilpert, MD, PhD
study chair · Mammazentrum am Krankenhaus Jerusalem, Hamburg

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carboplatin · Gemcitabine · Bevacizumab · Paclitaxel · Trabectedin · Cisplatin

Start the discussion